Alpha-Lipoic Acid

CAS Number	1077-28-7 (racemic DL-form; verified against PubChem CID 864)
Molecular Formula / MW	C8H14O2S2 / 206.33 g/mol
Chemical Class	Organosulfur compound — a cyclic disulfide (1,2-dithiolane) fatty acid; systematic name 5-(1,2-dithiolan-3-yl)pentanoic acid
Source	Endogenously synthesised in plants, animals, and humans; commercial material is chemically synthesised
Typical Standardisation	ALA powder, typically ≥98% by HPLC. Racemic unless specified as R-(+)-ALA
Primary Applications	Diabetic neuropathy symptom support, antioxidant and glutathione-regeneration formulation, metabolic support
Claim Strength (Overview)	Moderate to High for symptomatic diabetic polyneuropathy (multiple RCTs, meta-analyses); route of administration matters
Buy from Herbuno	Alpha-Lipoic Acid (ALA) Powder →

Name origin: Lipoic acid takes its name from the Greek lipos (fat), reflecting its lipophilic character; the alternative name thioctic acid references its sulfur (thio-) content and eight-carbon (octanoic) backbone. The "alpha" prefix distinguishes it from related dithiol compounds. Structurally it is a heterocyclic thia fatty acid — pentanoic acid bearing a 1,2-dithiolane ring — and it interconverts with its reduced dithiol form, dihydrolipoic acid, which is the basis of its redox chemistry. Traditional use: There is none, and it would be dishonest to manufacture one. Alpha-lipoic acid is not a traditional botanical remedy: it is an endogenous metabolite, first isolated in the 1950s and characterized as an essential cofactor for the oxidative decarboxylation reactions of the citric acid cycle. Its therapeutic use is a purely 20th-century pharmaceutical development, pioneered largely in Germany, where thioctic acid preparations have been prescribed for diabetic neuropathy for decades. Research trajectory: ALA research has been unusually disciplined and indication-focused. Rather than the diffuse "antioxidant supplement" trajectory that overtook many compounds, ALA was pursued through a coherent programme of German-led randomized controlled trials with named protocols — ALADIN I, ALADIN II, ALADIN III, SYDNEY, SYDNEY 2, NATHAN 1 — all targeting symptomatic diabetic polyneuropathy, producing a body of evidence that meta-analyses have been able to pool meaningfully. Commercial source: Commercial ALA is chemically synthesised, producing the racemic mixture of R- and S-enantiomers unless specifically manufactured as R-(+)-ALA. Only the R-enantiomer occurs naturally and functions as the enzymatic cofactor — a distinction with real formulation consequences discussed below.

---

Evidence for Alpha-Lipoic Acid Applications

Alpha-lipoic acid has an unusually coherent clinical evidence base for a supplement-category compound. A meta-analysis pooled four randomized, double-masked, placebo-controlled parallel-group trials — ALADIN I, ALADIN III, SYDNEY, and NATHAN II — comprising 1,258 patients (716 on alpha-lipoic acid, 542 on placebo), all using intravenous ALA at 600 mg/day for three weeks in diabetic patients with positive sensory symptoms of polyneuropathy scored daily by Total Symptom Score (Ziegler 2004). The intention-to-treat analysis found the treatment safe and significantly effective in alleviating positive neuropathic symptoms. This is a genuinely strong evidence base by botanical-and-supplement standards. Claim strength: Moderate to High.

The route-of-administration distinction is the single most important practical caveat, and it is frequently glossed over in supplement marketing. The strongest trials above used intravenous ALA. A separate meta-analysis and systematic review of oral ALA in diabetic sensorimotor peripheral neuropathy pooled ten RCTs (1,242 patients) with a subgroup analysis across 600, 1,200, and 1,800 mg/day doses, examining Total Symptom Score alongside nerve conduction and vibration perception outcomes (Nutrients 2023). An oral supplement is not pharmacologically equivalent to an intravenous infusion, and claims built on the IV literature should not be transferred to an oral product without acknowledging this. Claim strength: Moderate.

An honest reading of the trial series must note that not every result was positive. The ALADIN III study specifically found that three weeks of intravenous ALA followed by six months of oral treatment had no effect on neuropathic symptoms distinguishable from placebo to a clinically meaningful degree — though it did show a favourable effect on neuropathic deficits without significant adverse reactions. The distinction between symptom scores and objective deficits recurs across this literature and is a genuine source of interpretive difficulty rather than a technicality. Claim strength: Moderate.

The mechanistic account is well established and unusually specific for an "antioxidant." ALA is an essential cofactor for mitochondrial decarboxylation reactions in the citric acid cycle; separately, in its redox capacity it can act as a direct radical scavenger, as a cofactor regenerating reduced glutathione, and as a metal chelator. It is also amphipathic — soluble in both aqueous and lipid environments — which distinguishes it from most dietary antioxidants that are confined to one phase, and underlies the "universal antioxidant" description sometimes applied to it. Claim strength: Moderate (mechanistic).

The enantiomer question has real formulation consequences and is widely ignored. ALA has a chiral centre and exists as R- and S-enantiomers. Only the R-form occurs naturally and serves as the enzymatic cofactor; the S-form is a synthesis artefact of the racemic route. A standard "alpha-lipoic acid" product is racemic — half S-enantiomer — meaning a nominal 600 mg dose delivers roughly 300 mg of the biologically native form. Whether the S-enantiomer is merely inert or actively interferes with R-ALA uptake remains debated, but formulators specifying R-ALA should expect to pay for it and should not conflate the two. Claim strength: Moderate.

---

Dosage & Formulator Specification

Herbuno carries Alpha-Lipoic Acid (ALA) powder. Buyers requiring the R-(+)-enantiomer specifically, rather than the standard racemic material, should specify this at enquiry, as the two are commercially distinct grades at materially different cost.

Oral clinical dosing across the trial literature has centred on 600 mg/day, with meta-analytic subgroup analysis also examining 1,200 and 1,800 mg/day; 600 mg/day is the most commonly used and best-supported oral dose, and higher doses have not consistently shown proportionally greater benefit. Absorption is meaningfully reduced by food, and clinical protocols commonly specify administration on an empty stomach — roughly 30 minutes before eating — which is an actionable label instruction rather than a nicety. Onset of symptomatic effect in the trials was over weeks, not days.

Analytical verification should specify ALA content by HPLC (typically ≥98%) and, critically, should state whether the material is racemic or R-enantiomer-enriched, with chiral chromatography confirming enantiomeric ratio where R-ALA is being purchased. ALA is light- and heat-sensitive and prone to polymerisation, so storage conditions (typically 2–8°C, protected from light) and residual-solvent testing should be documented. The distinctive sulfurous odour of ALA is inherent to the molecule rather than a quality defect, but is a real palatability constraint in open-format products.

ALA is well tolerated across a large clinical exposure, with the pooled trial data explicitly finding treatment safe; mild gastrointestinal upset, nausea, and skin rash are the most commonly reported adverse effects. Two cautions warrant statement. Because ALA can lower blood glucose, caution is appropriate for individuals on antidiabetic medication, in whom it may compound the glucose-lowering effect. Separately, ALA is a metal chelator, which is part of its mechanism but which also creates theoretical potential to bind therapeutic mineral supplements or interfere with mineral status if taken concurrently — spacing administration is a reasonable precaution.

---

Frequently Asked Questions — Alpha-Lipoic Acid

Is oral alpha-lipoic acid as effective as intravenous?
This is the key caveat and it is often glossed over. The strongest evidence — the pooled ALADIN, SYDNEY and NATHAN trials — used intravenous ALA at 600 mg/day. There is a separate oral meta-analysis, but an oral supplement is not pharmacologically equivalent to an infusion, and claims built on the IV literature should not simply be transferred to an oral product.

What is the difference between R-ALA and standard alpha-lipoic acid?
Standard ALA is racemic — an equal mix of R- and S-enantiomers. Only the R-form occurs naturally and acts as the enzymatic cofactor; the S-form is a synthesis artefact. So a nominal 600 mg racemic dose delivers roughly 300 mg of the biologically native form. R-ALA is a distinct, more expensive grade and should be specified explicitly.

What dose of alpha-lipoic acid is used clinically?
Oral trials have centred on 600 mg/day, with meta-analytic subgroups also examining 1,200 and 1,800 mg/day. Higher doses have not consistently produced proportionally greater benefit. Absorption is reduced by food, so protocols commonly specify taking it on an empty stomach, around 30 minutes before eating.

Does alpha-lipoic acid have a traditional herbal history?
No, and it would be dishonest to imply otherwise. ALA is an endogenous metabolite first isolated in the 1950s and identified as a cofactor in the citric acid cycle. Its therapeutic use is a 20th-century pharmaceutical development, largely German-led, with no traditional botanical precedent.

Related compounds: Berberine, Myo-Inositol, EPA/DHA Omega-3, Quercetin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery